Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker
机构：[1]Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing, China[2]Department of Hematology/Oncology, Affiliated Cancer Hospital of Chongqing University, Chongqing, China[3]Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, China[4]Shanxi Provincial People's Hospital, Taiyuan, China[5]Department of Hematology, The Fourth Hospital of Hebei Medical University, Hebei, China临床科室血液内科河北医科大学第四医院[6]The Second Hospital of Dalian Medical University, Dalian, China[7]Inner Mongolia Xingan League Pepple's Hospital, Taiyuan, China[8]Chongqing University Cancer Hospital, Chongqing, China[9]Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, China[10]Shanxi Provincial People's Hospital, Taiyuan City, China[11]the Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
第一作者机构：[1]Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
推荐引用方式(GB/T 7714)：
Zhao Shihua,Liu Yao,Zhu Zunmin,et al.Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker[J].BLOOD.2022,140:1338-1339.doi:10.1182/blood-2022-165710.
APA：
Zhao, Shihua,Liu, Yao,Zhu, Zunmin,He, Jianxia,Liu, Lihong...&Huang, Wenrong.(2022).Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker.BLOOD,140,
MLA：
Zhao, Shihua,et al."Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker".BLOOD 140.(2022):1338-1339
医学